Regulatory T cells (Treg) are important regulators of anti-cancer immune responses, and an increase in Treg frequency was observed in the blood of cancer patients. Blood samples from 112 patients with head and neck squamous cell carcinoma antigen (HNSCC) were obtained at the time of tumour diagnosis, and lymphocyte subpopulations (CD3(+); CD3(-)CD16(+)CD56(+); CD4(+); CD8(+); CD19(+); CD4(+)CD45RA(+)) with emphasis on Treg counts (CD3(+)CD4(+)CD25(+)), complete blood count and tumour markers (squamous cell carcinoma [SCC]; CEA; alpha-1-antitrypsin [AAT]; Cyfra 21-1; C-reactive protein [CRP]) were analysed. The data were grouped according to TNM classification, and their significance for the course of the disease at an interval of 1 year after the end of the therapy was determined. The percentage of CD8(+) cells increased and the CD/D8 ratio decreased with tumour grade. The ratio of B lymphocytes decreased in patients with locoregional metastases (11.25%versus 9.22%). Treg (15.2%) and CD4(+) cells (45.3%) increased, while NK cells (11.8%) decreased in HNSCC patients compared to controls (9.0%, 38.1% and 15.8%, respectively). The data obtained at time of diagnosis were used to assess the significance of tumour markers (SCC, Cyfra 21-1 and AAT) for evaluation of prognosis. The erythrocyte counts (4.64 x 10(12)/l versus 4.45 x 10(12)/l) and haemoglobin levels (14.58 g/dl versus 14.05 g/dl) decreased, while Treg counts (8.91%versus 15.70%) increased in patients with early recurrence. Our results show that examination of these parameters could be helpful for prognostication in HNSCC patients and aid improvement of treatment strategy.

Charles University 1st Faculty of Medicine Department of Otorhinolaryngology Head and Neck Surgery University Hospital Motol 5 Uvalu Prague Czech Republic

Zobrazit více v PubMed

Groux H. Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation. 2003;75:8S–12S. PubMed

Carrier Y, Yuan J, Kuchroo VK, et al. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol. 2007;178:179–85. PubMed

Ladi E, Yin X, Chtanova T, et al. Thymic microenvironments for T cell differentiation and selection. Nature Immunol. 2006;7:338–43. PubMed

Randolph DA, Fathman CG. CD4 + CD25+ regulatory T cells and their therapeutic potential. Ann Rev Med. 2006;57:381–402. PubMed

Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 2005;6:345–52. PubMed

Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nature Rev. 2007;7:305–10. PubMed

Gallimore A, Godkin A. Regulatory T cells and tumour immunity – observations in mice and men. Immunology. 2008;123:157–63. PubMed PMC

Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 2004;10:942–9. PubMed

Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606–12. PubMed

Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766–72. PubMed

Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer. 2007;121:2473–83. PubMed

Schaefer C, Kim GG, Albers A, et al. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92:913–20. PubMed PMC

Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4+ CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301–11. PubMed

Alhamarneh O, Amarnath SM, Stafford ND, et al. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer. Head Neck. 2008;30:251–61. PubMed

Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets. 2007;7:633–42. PubMed

Karcher J, Dyckhoff G, Beckhove P, et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004;64:8057–61. PubMed

Forastiere A, Koch W, Trotti A, et al. Head and neck cancer. N Eng J Med. 2001;345:1890–900. PubMed

Plzak J, Betka J, Smetana K, Jr, et al. Galectin-3 – an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer. 2004;40:2324–30. PubMed

Nestor M, Ekberg T, Dring J, et al. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay. Tumour Biol. 2007;28:253–63. PubMed

Harper LJ, Piper K, Common J, et al. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med. 2007;36:594–603. PubMed

Cada Z, Boucek J, Dvorankova B, et al. Nucleostemin expression in squamous cell carcinoma of the head and neck. Anticancer Res. 2007;27:3279–84. PubMed

Richey LM, George JR, Couch ME, et al. Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13:6561–7. PubMed

Kim CH, Lee JS, Kang SO, et al. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncology. 2007;43:1021–5. PubMed

Wollenberg B, Jan V, Schmit UM, et al. Cyfra 21–1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res. 1996;16:3117–24. PubMed

Scheffold A, Murphy KM, Hofer T. Competition for cytokines: T(reg) cells take all. Nature Immunol. 2007;8:1285–7. PubMed

Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257–65. PubMed PMC

Bopp T, Jonuleit H, Schmitt E. Regulatory T cells–the renaissance of the suppressor T cells. Ann Med. 2007;39:322–34. PubMed

Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756–61. PubMed

Albers AE, Ferris RL, Kim GG, et al. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother. 2005;54:1072–81. PubMed PMC

Shevach EM. Regulatory/suppressor T cells in health and disease. Arthritis Rheum. 2004;50:2721–4. PubMed

Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12:465–72. PubMed

Kuss I, Hathaway B, Ferris RL, et al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:3755–62. PubMed

Kuss I, Hathaway B, Ferris RL, et al. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol. 2005;62:161–72. PubMed

Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007;25:862–8. PubMed

Chikamatsu K, Sakakura K, Whiteside TL, et al. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007;29:120–7. PubMed

Kim JW, Tsukishiro T, Johnson JT, et al. Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:5101–10. PubMed

Dong HP, Elstrand MB, Holth A, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol. 2006;125:451–8. PubMed

Palmesino E, Moepps B, Gierschik P, et al. Differences in CXCR4-mediated signaling in B cells. Immunobiology. 2006;211:377–89. PubMed

Lathers DM, Lubbers E, Beal NM, et al. Cultures derived from peripheral blood CD34+ progenitor cells of head and neck cancer patients and from cord blood are functionally different. Hum Immunol. 1999;60:1207–15. PubMed

The Head and Neck Squamous Cell Carcinoma Microenvironment as a Potential Target for Cancer Therapy

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma

A new strategy for the surgical management of RLN infiltrated by well-differentiated thyroid carcinoma

High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas